Date Filed | Type | Description |
03/24/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
03/23/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/23/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets Interactive Data |
03/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
03/03/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 10% stake in Metacrine, Inc. |
02/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an... |
02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 15.9% stake in Metacrine, Inc. |
02/03/2023 |
8-K
| Quarterly results |
02/01/2023 |
8-K
| Quarterly results |
01/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
01/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
12/19/2022 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 7.1% stake in Metacrine, Inc. |
12/14/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
12/08/2022 |
SC 13D
| BML Investment Partners, L.P. reports a 15.2% stake in Metacrine, Inc. |
10/11/2022 |
8-K
| Other Events Interactive Data |
09/28/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
09/27/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
09/26/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
09/07/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
09/06/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
09/06/2022 |
8-K
| Investor presentation
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Equillium, Inc., Metacrine, Inc., Equillium Acquisition Sub, Inc., and Triumph Merger Sub, Inc",
"Equillium to Acquire Metacrine in All-Stock Transaction",
"Investor Presentation" |
|
08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/09/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
08/05/2022 |
8-K
| Quarterly results |
05/18/2022 |
8-K
| Quarterly results |
05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/12/2022 |
8-K
| Quarterly results |
04/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/07/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/06/2022 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
|